Mer­ri­mack shut­ters a fail­ing PhII breast can­cer study for MM-302

Mer­ri­mack Phar­ma­ceu­ti­cals has de­cid­ed to scrap a Phase II breast can­cer study of MM-302 for treat­ment re­sis­tant pa­tients af­ter in­ves­ti­ga­tors de­ter­mined that they were on a one-way track to a fail­ure.

Mer­ri­mack $MACK was fol­low­ing up on some pos­i­tive ear­ly re­sults from a Phase I study that re­port­ed out in April, 2015, in­di­cat­ing that it may have been help­ing HER2-pos­i­tive pa­tients who had failed mul­ti­ple treat­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER